SI0670162T1 - Farmacevtske formulacije, ki vsebujejo raloksifere, surfaktant in vodotopno razredčilo - Google Patents

Farmacevtske formulacije, ki vsebujejo raloksifere, surfaktant in vodotopno razredčilo

Info

Publication number
SI0670162T1
SI0670162T1 SI9530581T SI9530581T SI0670162T1 SI 0670162 T1 SI0670162 T1 SI 0670162T1 SI 9530581 T SI9530581 T SI 9530581T SI 9530581 T SI9530581 T SI 9530581T SI 0670162 T1 SI0670162 T1 SI 0670162T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical formulations
raloxifere
watersoluble
diluent
surfactant
Prior art date
Application number
SI9530581T
Other languages
English (en)
Inventor
Lowell Lee Gibson
Kerry John Hartauer
Julian Larry Stowers
Stephanie Ann Sweetana
Arvind Lavji Thakkar
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI0670162T1 publication Critical patent/SI0670162T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SI9530581T 1994-03-02 1995-02-28 Farmacevtske formulacije, ki vsebujejo raloksifere, surfaktant in vodotopno razredčilo SI0670162T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20491594A 1994-03-02 1994-03-02
EP95301291A EP0670162B1 (en) 1994-03-02 1995-02-28 Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent
SG1997000220A SG65636A1 (en) 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SI0670162T1 true SI0670162T1 (sl) 2002-06-30

Family

ID=26665140

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530581T SI0670162T1 (sl) 1994-03-02 1995-02-28 Farmacevtske formulacije, ki vsebujejo raloksifere, surfaktant in vodotopno razredčilo

Country Status (22)

Country Link
EP (1) EP0670162B1 (sl)
JP (1) JP3574210B2 (sl)
CN (1) CN1098684C (sl)
AT (1) ATE211910T1 (sl)
AU (1) AU684882B2 (sl)
BR (1) BR9500758A (sl)
CA (1) CA2143263C (sl)
CZ (1) CZ286119B6 (sl)
DE (1) DE69524981T2 (sl)
DK (1) DK0670162T3 (sl)
ES (1) ES2166799T3 (sl)
FI (1) FI117042B (sl)
HU (1) HU225418B1 (sl)
IL (1) IL112746A (sl)
NO (1) NO314286B1 (sl)
NZ (1) NZ270588A (sl)
PL (1) PL178858B1 (sl)
PT (1) PT670162E (sl)
RU (1) RU2118540C1 (sl)
SG (1) SG65636A1 (sl)
SI (1) SI0670162T1 (sl)
ZA (1) ZA951497B (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CZ300341B6 (cs) * 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
ZA979723B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2001042186A1 (fr) 1999-12-13 2001-06-14 Chugai Seiyaku Kabushiki Kaisha Compose a chaine laterale hydroxycarbonyl-halogenoalkyle
JP4798924B2 (ja) * 1999-12-13 2011-10-19 中外製薬株式会社 ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
PL363311A1 (en) * 2001-04-24 2004-11-15 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnfalpha
AU2003266940B2 (en) 2002-09-30 2007-02-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
IN2014MN00380A (sl) 2006-06-30 2015-06-19 Iceutica Pty Ltd
EP2197423B1 (en) * 2007-10-16 2014-12-03 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
WO2009080364A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
WO2010121328A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of indomethacin
EP2448562B1 (en) * 2009-07-02 2013-11-06 Synthon B.V. Raloxifene composition
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
DK2925320T3 (da) 2012-11-30 2021-05-10 Pharmathen Sa Hidtil ukendt fremgangsmåde til forbedring af bio-tilgængeligheden af lægemidler med lav vandopløselighed
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
KR102612983B1 (ko) * 2016-09-30 2023-12-13 한미약품 주식회사 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
ATE211910T1 (de) 2002-02-15
CZ286119B6 (cs) 2000-01-12
CA2143263A1 (en) 1995-09-03
FI117042B (fi) 2006-05-31
HU225418B1 (en) 2006-11-28
NO314286B1 (no) 2003-03-03
CZ49995A3 (en) 1995-10-18
NZ270588A (en) 1996-01-26
IL112746A0 (en) 1995-05-26
BR9500758A (pt) 1995-10-24
DE69524981T2 (de) 2002-08-29
NO950799L (no) 1995-09-04
RU2118540C1 (ru) 1998-09-10
FI950947A0 (fi) 1995-03-01
HU9500635D0 (en) 1995-04-28
JPH07277973A (ja) 1995-10-24
ZA951497B (en) 1996-08-23
DK0670162T3 (da) 2002-03-11
EP0670162A1 (en) 1995-09-06
HUT72661A (en) 1996-05-28
AU1354895A (en) 1995-09-07
PL307491A1 (en) 1995-09-04
CN1112420A (zh) 1995-11-29
IL112746A (en) 1999-12-31
SG65636A1 (en) 1999-06-22
DE69524981D1 (de) 2002-02-21
AU684882B2 (en) 1998-01-08
EP0670162B1 (en) 2002-01-16
JP3574210B2 (ja) 2004-10-06
CA2143263C (en) 2002-01-08
NO950799D0 (no) 1995-03-01
PT670162E (pt) 2002-06-28
FI950947A (fi) 1995-09-03
ES2166799T3 (es) 2002-05-01
PL178858B1 (pl) 2000-06-30
CN1098684C (zh) 2003-01-15

Similar Documents

Publication Publication Date Title
SI0670162T1 (sl) Farmacevtske formulacije, ki vsebujejo raloksifere, surfaktant in vodotopno razredčilo
EP0698393A4 (en) SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME
AU7221298A (en) Compounds
GB9922121D0 (en) Formulation
ITRM940324A0 (it) "formulazioni galenione contenenti macrolidi".
EP0948965A4 (en) STABLE MEDICAL COMPOSITIONS CONTAINING 4,5-EPOXYMORPHINE DERIVATIVES
EP0631789A3 (de) Vorrichtung zum Gasaustausch, insbesondere Oxygenierung in Blut.
EP0634459A3 (de) Formulierungen.
EP0395287A3 (en) Dentifrice compositions
HUT71398A (en) Derivatives of dolastatin
AU570328B2 (en) Solid medicament formulations containing dihydropyridines
AU8149291A (en) (2r)-2-{di(2-propyl)phosphonylmethoxy}-3-p- toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
TW270083B (sl)
AU2698992A (en) Freeflowing alkaline detergent, and agents for the preparation thereof
CA2216978A1 (en) Dentifrice formulations containing liquid polyoxyalkylene compounds miscible in a liquid, polyalkylene glycol carrier
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
GR3022709T3 (en) Aerosol composition containing fusafungine.
MY117590A (en) Orally administerable pharmaceutical formulations
IT1258818B (it) Composizioni farmaceutiche orali a base di n5-metiltetraidrofolato di calcio
AU8086098A (en) Delta 12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
IT234658Y1 (it) Corpo per cassetta postale.
AU8943398A (en) Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
IT228571Y1 (it) Involucro d'imballaggio,in particolare per feretri.